Anderson P
Acta Pharmacol Toxicol (Copenh). 1986;58 Suppl 2:43-57. doi: 10.1111/j.1600-0773.1986.tb02520.x.
Verapamil and nifedipine are the most frequently used calcium channel blocking agents in Sweden at present time. The pharmacokinetics of verapamil has been described both in healthy volunteers as well as in patients with supraventricular arrhythmias, angina pectoris, liver cirrhosis, hypertrophic cardiomyopathy or hypertension. Intravenous pharmacokinetics of nifedipine has been investigated in healthy volunteers and oral pharmacokinetics in healthy volunteers as well as in patients with hypertension. The pharmacokinetics of verapamil and of one of its metabolites, norverapamil, is changed after multiple oral dosing as has been described in patients with supraventricular tachyarrhythmias, angina pectoris or in patients with essential hypertension. Plasma concentration-effect relationships have been established for verapamil in different clinical situations and in a few cases also for nifedipine. An update of the pharmacokinetics of these two important calcium channel blocking agents is presented.
维拉帕米和硝苯地平是瑞典目前最常用的钙通道阻滞剂。维拉帕米的药代动力学已在健康志愿者以及患有室上性心律失常、心绞痛、肝硬化、肥厚型心肌病或高血压的患者中进行了描述。硝苯地平的静脉药代动力学已在健康志愿者中进行了研究，口服药代动力学则在健康志愿者以及高血压患者中进行了研究。如在室上性快速心律失常、心绞痛患者或原发性高血压患者中所描述的那样，多次口服给药后，维拉帕米及其一种代谢产物去甲维拉帕米的药代动力学发生了变化。已经在不同临床情况下建立了维拉帕米的血浆浓度-效应关系，在少数情况下也建立了硝苯地平的血浆浓度-效应关系。本文介绍了这两种重要钙通道阻滞剂药代动力学的最新情况。
